Go Pro

Oncobiologics (OTLK) 10K Form and Latest SEC Filings 2026

Oncobiologics logo
$1.73 +0.18 (+11.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.72 0.00 (-0.29%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Oncobiologics SEC Filings & Recent Activity

Oncobiologics (NASDAQ:OTLK) has submitted 465+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Oncobiologics's financial statements. The most recent filing was a Form DEFA14A submitted on July 10, 2026.

Form 4
Outlook Therapeutics, Inc. Reports Ownership Change on Jun. 3, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Oncobiologics Files Current Report on Jun. 26, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Oncobiologics Files Quarterly Report on May. 15, 2026

The 10-Q contains Oncobiologics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Oncobiologics SEC Filing History

Browse Oncobiologics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
07/10/2026 5:02 AM
Oncobiologics (1649989) Filer
Form DEFA14A
06/26/2026 4:30 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/16/2026 7:46 AM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2026 5:03 PM
Haddadin Yezan Munther (1718004) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2026 8:30 PM
GMS Ventures & Investments (1804598) Reporting
Oncobiologics (1649989) Issuer
Sukhtian Ghiath M. (1717441) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2026 8:31 PM
GMS Ventures & Investments (1804598) Filed by
Oncobiologics (1649989) Subject
Form SCHEDULE 13D/A
06/01/2026 4:00 PM
Oncobiologics (1649989) Filer
Form DEF 14A
06/01/2026 4:00 PM
Oncobiologics (1649989) Filer
Form DEFA14A
06/01/2026 8:15 AM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2026 3:30 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2026 7:30 AM
Oncobiologics (1649989) Filer
Form 424B5
05/28/2026 4:09 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/27/2026 2:24 PM
Haddadin Yezan Munther (1718004) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 2:29 PM
Oncobiologics (1649989) Issuer
Sukhtian Faisal Ghiath (1716033) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 2:15 PM
HILZINGER KURT J (1191504) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 2:20 PM
Oncobiologics (1649989) Issuer
THURMAN RANDY H (1204059) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2026 6:15 AM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/22/2026 4:03 PM
Oncobiologics (1649989) Filer
Form PRE 14A
05/15/2026 3:31 PM
Oncobiologics (1649989) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/13/2026 4:12 PM
Oncobiologics (1649989) Filer
Form 424B5
05/13/2026 3:36 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2026 4:17 PM
INTRACOASTAL CAPITAL, LLC (1646799) Filed by
Oncobiologics (1649989) Subject
Form SCHEDULE 13G
04/23/2026 3:30 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/23/2026 6:30 AM
Oncobiologics (1649989) Filer
Form 424B5
04/21/2026 3:15 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/07/2026 3:15 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2026 4:04 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/23/2026 4:18 PM
Oncobiologics (1649989) Filer
Form 424B5
03/16/2026 8:00 AM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/11/2026 4:15 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2026 3:30 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 7:30 AM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/05/2026 10:48 AM
Oncobiologics (1649989) Subject
SPHERA FUNDS MANAGEMENT LTD. (1496201) Filed by
Form SCHEDULE 13G/A
01/26/2026 4:01 PM
Oncobiologics (1649989) Filer
Form DEF 14A
01/26/2026 4:02 PM
Oncobiologics (1649989) Filer
Form DEFA14A
01/26/2026 4:03 PM
Oncobiologics (1649989) Filer
Form ARS
01/02/2026 6:30 AM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/19/2025 4:01 PM
Oncobiologics (1649989) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
12/19/2025 7:30 AM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/03/2025 4:01 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/21/2025 8:00 AM
Empery Asset Management, LP (1469336) Filed by
Oncobiologics (1649989) Subject
Form SCHEDULE 13G/A
Trump's New Dollar (Ad)

Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel

Watch the free briefing and see the three steps to prepare today
10/03/2025 7:37 PM
Huang Andong (1815678) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 7:12 PM
Haller Julia A (1656082) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 6:55 PM
HILZINGER KURT J (1191504) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 6:45 PM
Gangolli Julian S (1532023) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 6:14 PM
Auffarth Gerd (1649867) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 6:20 PM
Haddadin Yezan Munther (1718004) Reporting
Oncobiologics (1649989) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 5:52 PM
Oncobiologics (1649989) Issuer
Sukhtian Faisal Ghiath (1716033) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 6:00 PM
Oncobiologics (1649989) Issuer
THURMAN RANDY H (1204059) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/29/2025 4:00 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/05/2025 4:00 PM
Oncobiologics (1649989) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 4:15 PM
GREAT POINT PARTNERS LLC (1281446) Filed by
Oncobiologics (1649989) Subject
Form SCHEDULE 13G/A
08/14/2025 3:15 PM
Oncobiologics (1649989) Subject
TANG CAPITAL MANAGEMENT LLC (1232621) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Oncobiologics SEC Filings - Frequently Asked Questions

Oncobiologics (OTLK) has submitted 465+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Oncobiologics's fiscal year ends on September 30. The company typically files its 10-K annual report by the end of November, covering the prior fiscal year's financial results. Key financial data from these reports is available on Oncobiologics's financial statements page.

The most recent filing was a Form DEFA14A submitted on July 10, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:OTLK) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners